Table 2.
Tumor and normal tissue distribution at 24 h post-injection of increasing mass amounts of 64Cu-NOTA-pertuzumab F(ab')2 * *in mice with subcutaneous SK-OV-3 human ovarian cancer xenografts.
| Percent injected dose/g (%ID/g) | ||||
|---|---|---|---|---|
| Tissue |
5 µg |
50 µg |
100 µg |
200 µg |
| Blood | 0.6 ± 0.0 | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.1 |
| Heart | 2.3 ± 0.3 | 2.2 ± 0.4 | 2.0 ± 0.2 | 1.9 ± 0.3 |
| Lungs | 2.1 ± 0.2 | 2.1 ± 0.4 | 1.9 ± 0.2 | 2.0 ± 0.3 |
| Liver | 10.7 ± 1.3 | 10.9 ± 3.3 | 9.3 ± 2.1 | 7.8 ± 1.3 |
| Kidneys | 60.0 ± 4.7 | 65.6 ± 16. 2 | 54.8 ± 3.9 | 52.4 ± 12.8 |
| Spleen | 11.9 ± 0.9 | 11.5 ± 5.8 | 9.0 ± 1.4 | 7.4 ± 0.4 |
| Stomach | 2.8 ± 2.9 | 1.2 ± 0.2 | 1.1 ± 0.1 | 1.1 ± 0.1 |
| Intestines | 2.1 ± 0.1 | 2.0 ± 0.4 | 1.7 ± 0.2 | 1.8 ± 0.4 |
| Muscle | 0.4 ± 0.0 | 0.4 ± 0.2 | 0.4 ± 0.1 | 0.4 ± 0.1 |
| Bone | 1.9 ± 0.2 | 1.6 ± 0.5 | 1.6 ± 0.2 | 1.4 ± 0.2 |
| Skin | 1.0 ±0.4 | 1.0 ± 0.6 | 1.5 ± 1.0 | 1.5 ± 0.8 |
| Tumor | 8.2 ± 2.6 | 9.8 ± 5.1 | 8.2 ± 2.1 | 5.8 ± 1.3 |
Values shown are mean ± SD (n = 4).
*
Mice were intravenously administered 1-3 MBq of 64Cu-NOTA-pertuzumab F(ab')2.